Intra-Cellular Therapies, Inc. provides sales guidance for the fiscal year 2023. Full year 2023 CAPLYTA net product sales guidance increased to $460 to $470 million from the previous range of $445 to $465 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
66.84 USD | +1.72% | -0.24% | -6.67% |
05-07 | Sector Update: Health Care Stocks Steady Pre-Bell Tuesday | MT |
05-07 | Transcript : Intra-Cellular Therapies, Inc., Q1 2024 Earnings Call, May 07, 2024 |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-6.67% | 6.94B | |
-0.07% | 89.46B | |
+2.76% | 40.74B | |
-9.06% | 33.03B | |
+55.32% | 24.68B | |
-16.61% | 15.12B | |
-9.14% | 12.81B | |
-12.11% | 11.79B | |
-43.61% | 11.64B | |
+7.79% | 8.9B |
- Stock Market
- Equities
- ITCI Stock
- News Intra-Cellular Therapies, Inc.
- Intra-Cellular Therapies, Inc. Provides Sales Guidance for the Fiscal Year 2023